ClinicalTrials.gg
TerminatedNCT00037180Updated Sep 29, 2008

For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy

A Phase 2 interventional study of Celecoxib and Irinotecan in Neoplasm Metastasis and Colorectal Neoplasms, sponsored by Pfizer. Terminated at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-09-29.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 48 studies in Neoplasm Metastasis by Pfizer — 5 open to participants now, 5 under way, 3 of them phase 3. Neoplasm Metastasis · Pfizer.

Enrollment
14th of 43
212 · median 75
Started
2002
the only one that year
Phase 2
7 of 48
none open now
Registered
2nd of 48
by date

Among the 48 studies in Neoplasm Metastasis by Pfizer, this one is the 14th largest by enrollment of the 43 interventional ones that give a count, is the only one that started in 2002, is one of 7 in phase 2, and was the 2nd registered.

Neoplasm Metastasis

4,048 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

5 of the 48 studies in Neoplasm Metastasis by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Neoplasm Metastasis by Pfizer, or all of them as a file.
02

Study summary

The Diarrhea Prevention with an investigational drug trial, will evaluate whether adding an investigational drug to the standard treatment for advanced colorectal cancer can reduce the amount of diarrhea a patient experiences. The standard and approved treatment for patients with metastatic colorectal cancer is repeated cycles of chemotherapy consisting of a combination of irinotecan (also known as CPT-11, Camptosar), 5-fluorouracil (also known as 5FU), and leucovorin (also known as LV). Preclinical data from animal models suggest that the investigational drug may offer an effective means for preventing CPT-11/5FU/LV-induced diarrhea. It is also hypothesized that the investigational drug-mediated anti-angiogenesis could induce a favorable tumor response.

03

Conditions studied

  • Neoplasm Metastasis
  • Colorectal Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of colorectal cancer (either newly diagnosed or recurrent disease) with evidence of disease and present or past histological documentation of adenocarcinoma of the colon or rectum.
  • Tumor must be measureable.
  • Resolution of all acute toxic effects of any prior radiotherapy or surgical procedure.
  • performance status 0 or 1. Age >= 18 years.
  • Required baseline laboratory.
  • Negative pregnancy test.
  • Willingness and ability to comply with the treatment plan.

Exclusion criteria

Exclusion Criteria:

  • Current enrollment in another clinical trial.
  • Prior therapy for colorectal cancer \<= 6 months prior to randomization.
  • Prior systemic anticancer therapy or intra-arterial cytotoxic chemotherapy given as treatment for colorectal cancer.
  • Known allergy to CPT-11, 5-FU, LV, celecoxib, other COX-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDS), salicylates, or sulfonamides.
  • Chronic concomitant use of full-dose aspirin, other NSAIDs or other COX-2 inhibitors for a chronic nonmalignant condition.
  • A requirement for chronic concomitant use of low-dose (cardioprotective) aspirin.
  • Chronic oral use for treatment of a non-malignant condition.
  • Known ulceration of the gastric or duodenal mucosa \<= 30 days prior to randomization.
  • Need for concomitant fluconazole or lithium.
  • Any known significant bleeding disorder.
  • Active inflammatory bowel disease or chronic diarrhea.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
212 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of NCI CTC grade 2-4 diarrhea during the first cycle (6 weeks) of CPT-11/5-FU/LV chemotherapy

Secondary outcomes

  1. Severity of all grades of diarrhea, overall and by cycle

  2. Duration of diarrhea, by cycle

  3. Diarrhea grade, by day, by cycle

  4. Stool count, by day, by cycle

  5. Severity of asthenia (fatigue), by week.

  6. Asthenia will be assessed with the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) scale.

  7. Duration of asthenia, by week, as measured by the FACIT-Fatigue scale

  8. Type, frequency, severity, timing, and relatedness of all adverse events CPT-11/5-FU/LV treatment administration as characterized by median, mean, and range of doses given; dose modifications, omissions, and delays; and actual and relative dose intensity

  9. Compliance with celecoxib use Incidence, quantity, and duration of loperamide use

  10. Tumor response rate (overall and confirmed)using the World Health Organization [WHO] Response Evaluation Criteria in Solid Tumors [RECIST 2000]

  11. Serum tumor marker (carcinoembryonic antigen [CEA]) response rate (as characterized by a 50% reduction from baseline)

  12. Time to tumor progression (TTP)

  13. Time to treatment failure (TTF)

  14. Survival Post-study anticancer treatment

  15. Peak plasma levels and AUC 0-24 values for CPT-11 and its major metabolites, SN-38, SN-38 glucuronide (SN-38G), and aminopentane carboxylic acid (APC)

  16. Inflammatory cytokines which may serve as biomarkers for cancer-related outcomes Beta-glucuronidase as a potential biomarker for tumor response

  17. Health resource utilization (collected data to be evaluated separately from this protocol)

07

Study locations

12 sites
  • Pfizer Investigational Site
    Mobile, Alabama 36685, United States
  • Pfizer Investigational Site
    Ft. Lauderdale, Florida 33308, United States
  • Pfizer Investigational Site
    Port St. Lucie, Florida 34952, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60631, United States
  • Pfizer Investigational Site
    St. Joseph, Missouri 64507, United States
  • Pfizer Investigational Site
    St. Louis, Missouri 63136, United States
  • Pfizer Investigational Site
    Buffalo, New York 14215, United States
  • Pfizer Investigational Site
    Williamsville, New York 14221, United States
  • Pfizer Investigational Site
    Altoona, Pennsylvania 16601, United States
  • Pfizer Investigational Site
    Puyallup, Washington 98372, United States
  • Pfizer Investigational Site
    Yakima, Washington 98902, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin 53215, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2002 and a completion of Jan 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2002
First posted
May 17, 2002
Start
Apr 2002
CompletionActual
Jan 2003
Last update
Sep 29, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00037180
Lead sponsor
Pfizer
First posted
May 17, 2002
Start date
Apr 2002
Completion
Jan 2003
Last update
Sep 29, 2008

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion